Research Articles
%22%20%2F%3E%3C%2Fsvg%3E)
Most cancer patients receive care in the community, yet few studies have evaluated the effectiveness of clinical programs outside of academic or National Cancer Institute (NCI)-designated cancer centers.
%22%20%2F%3E%3C%2Fsvg%3E)
Total body irradiation (TBI) with or without cranial radiation boost (CRB) is an integral component of conditioning prior to allogeneic hematopoietic cell transplantation (allo-HCT) in acute lymphoblastic leukemia (ALL).
%22%20%2F%3E%3C%2Fsvg%3E)
Multiple myeloma remains incurable, and management involves cycles of treatment response, disease relapse, and further therapy. Thus, the EMMY study was designed to annually assess the therapeutic management of MM.
%22%20%2F%3E%3C%2Fsvg%3E)
Our study suggests that in patients with primary refractory DLBCL without initial progressive disease after frontline R-CHOP, the depth of response to SC before HDC–ASCT is predictive of relapse.
Our single-center experience can help prompt diagnosis and therapeutic intervention in daily clinical practice.
The primary symptom of severe hemophilia is spontaneous and recurrent bleeding into joints, muscles, and soft tissues. Unpreventable bleeding may cause arthropathy, chronic discomfort, and muscular atrophy.
%22%20%2F%3E%3C%2Fsvg%3E)
Antibiotic DE in neutropenic HCT or CAR T-cell therapy patients treated with broad-spectrum antibiotics for at least three days appears to be a safe and effective practice.
%22%20%2F%3E%3C%2Fsvg%3E)
Post-procedure care focuses on pain management, blood cell recovery, and the psychological support necessary to regain a high-quality-of-life existence. Hematopoietic stem donors are giving part of themselves, saving another’s life.
Patients with a low ALC on day +30 face a higher risk of HHV6 reactivation and may require careful monitoring.
%22%20%2F%3E%3C%2Fsvg%3E)
In conclusion, daratumumab is tolerable amongst Asian patients, including the elderly, and patients with severe renal impairment and chronic lung diseases.
The risk of SM development may be due to genetic predisposition, immune dysregulation, or treatment-induced immune suppression.
Plasma cell leukemia (PCL) is a rare, aggressive subtype of multiple myeloma (MM) with a poor prognosis. We deal with racial disparities that affect MM patients.